Renal sympathetic denervation: the jury is still out.

摘要

The Symplicity HTN-2 Investigators deserve credit for building on the proof-of-principle study, and for addressing a substantial concern (the need for a randomised trial) by undertaking the first RCT of renal sympathetic denervation in patients with treatment-resistant hypertension. Hypertension isthe most common indication for lifelong treatment, mainly because of the incontrovertible reductions in cardiovascular events.Despite the abundance of antihypertensive drugs, control of blood pressure rates remains disappointingly low worldwide. Many patients who are uncontrolled present resistant hypertension (ie, uncontrolled blood pressure despite the use of optimum doses of three antihypertensive drugs, one being a diuretic).